AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02106910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge
Description: The Cytosponge is a simple, non-endoscopic device developed for endoscopic screening of subjects at risk for Barrett's esophagus (BE) by investigators at the University of Cambridge in the U.K. The Cytosponge is an ingestible gelatin capsule enclosing a compressed spherical polyurethane mesh sponge of 3 cm diameter, the center of which is attached to a string (Astralen, braided synthetic non-absorbable suture) (Figure 1). The capsule and string are swallowed with water. The string is held at the mouth without tension by means of a 7 cm cardboard tab attached to the string, and esophageal peristalsis and gravity move the capsule into the stomach. After 5 to 7 minutes (during which the gelatin capsule dissolves and the sponge is liberated), the sponge is withdrawn by gentle traction on the string and as it does so, collects cells from the lining of the esophagus. The sponge is placed in fixative for 48 hours, then the cells are pelleted, and processed into paraffin blocks
Study NCT02712255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Planning
Description: CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter.
Study NCT02712255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Planning
Description: CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of only one person in the dyad: the patient.
Study NCT02712255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Planning
Description: CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.~Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.~The plan focuses on physical activity of both persons within the dyad (the patient and the partner) and include some plans for joint physical activity.
Study NCT02712255 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a patient-partner dyad and discusses individual guidelines for both dyadic partners.
Study NCT01664715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 150 Min/Week
Description: Performs 150 min/wk of planned moderate intensity aerobic exercise.
Study NCT01664715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 225 Min/Week
Description: Performs 225 min/wk of planned moderate intensity aerobic exercise.
Study NCT01664715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 300 Min/Week
Description: Performs 300 min/wk of planned moderate intensity aerobic exercise.
Study NCT02240875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 1 x 10^10 vp
Description: Low dose cAd3-EBO Z
Study NCT02712255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a patient-partner dyad and discusses individual guidelines for both dyadic partners.
Study NCT02405754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Corus CAD (ASGES)
Description: Age/Sex/Gene Expression Score - ASGES
Study NCT03300960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Provera 10 mg.
Description: One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.
Study NCT03300960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganirelix (GnRH antagonist)
Description: One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
Study NCT03312543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Mask
Description: A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the active light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
Study NCT03312543 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Mask
Description: A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the sham light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
Study NCT03126370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF with a boosted protease inhibitor
Description: Participants who are already taking tenofovir disoproxil fumarate 300 mg (in the form of Viread or Truvada) in combination with either a ritonavir- or cobicistat-boosted protease inhibitor for HIV treatment will continue to take their prescribed treatment for 12 weeks after enrollment.~Other: Blood draws for tenofovir PK, renal function assessment
Study NCT01472185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine tablets administered orally twice daily.
Study NCT01472185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ranolazine administered orally twice daily.
Study NCT03126370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF with a boosted protease inhibitor
Description: Participants will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide 25 mg/emtricitabine 200 mg with a boosted protease inhibitor.~Other: Blood draws for tenofovir PK, renal function assessment
Study NCT03126370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF with a boosted protease inhibitor and LDV/SOF
Description: After taking tenofovir alafenamide/emtricitabine for 12 weeks, participants will then start taking ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni) in combination with the tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for 4 weeks. Subjects will then return to taking tenofovir alafenamide 25 mg/emtricitabine 200 mg (Descovy) and a boosted protease inhibitor for the final 12 weeks.~Other: Blood draws for tenofovir PK, renal function assessment
Study NCT04014309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive and survivorship care program
Description: Provision of routine systematic screening using distress thermometer and problem list with accompanying supportive care nurse service.
Study NCT04014309 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care
Study NCT03865134 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Snellen Test
Description: Visual acuity measurement
Study NCT03865134 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Autorefractometer
Description: Refraction measurement
Study NCT03865134 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Titmus Stereo Fly Test
Description: Stereopsis measurement
Study NCT03865134 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Kohlerans Tomography
Description: Retinal development measurement
Study NCT03865134 — intervention group
Intervention type: BEHAVIORAL
Intervention: Investigation of Visual Motor Integration
Description: Investigation of visual motor integration, motor coordination and visual perception by Beery- Buktenica Developmental Test of Visual Motor Integration.
Study NCT03865134 — intervention group
Intervention type: BEHAVIORAL
Intervention: Peabody Developmental Motor Scales - II
Description: Evaluation of motor development
Study NCT01472185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to match ranolazine administered orally twice daily.
Study NCT03865134 — intervention group
Intervention type: BEHAVIORAL
Intervention: World Health Organization Quality of Life - BREF
Description: Assesment of quality of life
Study NCT01472185 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Participants are instructed to continue the diet regimen prescribed by their physician.
Study NCT01472185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants are instructed to continue the diet regimen prescribed by their physician.
Study NCT01472185 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Participants are instructed to continue the exercise regimen prescribed by their physician.
Study NCT02240875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 2.5 x 10^10 vp
Description: Medium dose cAd3-EBO Z
Study NCT02240875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBO Z at 5 x 10^10 vp
Description: High dose cAd3-EBO Z
Study NCT03865134 — intervention group
Intervention type: BEHAVIORAL
Intervention: State - Trait Anxiety Inventory
Description: Assesment of anxiety
Study NCT02240875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4.4x10^8 TCID50s MVA-BN® Filo
Description: High dose MVA-BN® Filo
Study NCT02240875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2.2x10^8 TCID50s MVA-BN® Filo
Description: Low dose MVA-BN® Filo
Study NCT01472185 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants are instructed to continue the exercise regimen prescribed by their physician.
Study NCT02240875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4.4 x 10^7 TCID50s MVA-BN® Filo
Description: Very low dose MVA-BN® Filo
Study NCT02483299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Study NCT02483299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage tablets and Victoza
Study NCT00138632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787
Description: Visudyne® + PTK787, 500 mg/day
Study NCT00138632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787
Description: Visudyne® + PTK787 1000 mg/day
Study NCT00138177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00138177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00138177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study NCT00138177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT04095273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elimusertib (BAY1895344)
Description: Study drugs will be administered as scheduled
Study NCT02830841 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning(RIPC)
Description: After anesthesia induction, donors or recipients will be treated with automated blood pressure cuffs on their upper arms to receive RIPC by cuff inflation (to 15mmHg above systolic pressure) for 5 minutes and left inflated for 5 minutes. The cuff will then be deflated to 0 mm Hg and left uninflated for 5 minutes. This cycle will be performed 3 times in total.
Study NCT04095273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Keytruda®)
Description: Study drugs will be administered as scheduled
Study NCT00138632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Visudyne® + Placebo
Study NCT02396940 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D HD laparoscopy
Description: Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
Study NCT02396940 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 2D HD laparoscopy
Description: Placebo
Study NCT02519556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiatop
Description: Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
Study NCT01933217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Study NCT01933217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02291744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of primary lesion
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle, and resection of primary lesion with metastatic colon cancer
Study NCT03469609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mucous fistula refeeding
Description: Transfer of infants' own stool
Study NCT02291744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
Study NCT02291744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
Study NCT03981952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Invasive Salmonella Disease Vaccine (6.25 µg)
Description: 6.25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
Study NCT03981952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Invasive Salmonella Disease Vaccine (12 µg)
Description: 12 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
Study NCT03981952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Invasive Salmonella Disease Vaccine (25 µg)
Description: 25 µg of the conjugate vaccine is administered via one intramuscular injection into the deltoid muscle on Study Day 1.
Study NCT03981952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Invasive Salmonella Disease Vaccine (highest, well-tolerated dose among Cohorts A-C)
Description: The highest, well-tolerated dose of the conjugate vaccine among Cohorts A-C is administered via one or two intramuscular injection(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
Study NCT03981952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.5 mL of buffer and preservative is administered via one or two intramuscular injections(s) into the deltoid muscle on Study Day 1 (and 29 if two doses are given).
Study NCT03647137 — intervention group
Intervention type: OTHER
Intervention: Detailed motor testing, including FoG, in PD subjects
Description: Subjects with PD with and without freezing of gait (FoG) will undergo a biomechanical assessment during a FoG provocation protocol in both the dopaminergic on and off state.
Study NCT03757468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthodontic - maxillary expansion
Description: After appliance placement, the screw (hyrax or leaf type) will be activated until overcorrection. Expansion will be considered adequate when the occlusal surface of the first maxillary palatal cusp contact the occlusal surface of the mandibular first molar facial cusp. When will be achieved, the expander will stay in place for 10 months.
Study NCT03757468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic - maxillary expansion
Description: After appliance placement, the screw (hyrax or leaf type) will be activated until overcorrection. Expansion will be considered adequate when the occlusal surface of the first maxillary palatal cusp contact the occlusal surface of the mandibular first molar facial cusp. When will be achieved, the expander will stay in place for 10 months.
Study NCT04129944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UBX0101
Description: Investigational drug intra-articular injection
Study NCT04129944 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intra-articular injection
Study NCT00178724 — intervention group
Intervention type: OTHER
Intervention: No Treatment Given
Description: Intervention is not given.
Study NCT02943460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilofexor
Description: Tablet(s) administered orally once daily with food
Study NCT04043702 — intervention group
Intervention type: DRUG
Intervention: The intervention being studied
Description: Intervention Other Names have not been specified
Study NCT02645487 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Radiation, Stereotactic Radiosurgery Size \<= 1cm: 24 Gray (Gy); + 3 Gy incremental escalation up to 30 Gy >1-2cm: 21 Gy; + 3 Gy incremental escalation up to 27 Gy >2-3cm: 18 Gy; + 3 Gy incremental escalation up to 24 Gy
Study NCT02105701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir + Elbasvir
Description: FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
Study NCT03514693 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: Ipsilateral circumferential PVI is the recommended PVI strategy. The success of PVI is defined as the achievement of the dissociation of PV potentials in all PVs. Disappearance of PV potentials is reconfirmed at the end of the procedure, a minimum of 20 minutes after the initial success of PVI.
Study NCT03514693 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PVI plus additional ablation
Description: In addition to PVI, CFAE ablation, linear ablation, or both; the choice of which is decided by the physician
Study NCT00694590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Drug Course 1: plerixafor (20mg/mL). Dose escalation starting with 80 mcg/kg then 160, 240, 320, 420, and 540 mcg/kg, or to de-escalate to 40mcg/kg. Dosing 3 times/week for 3 weeks beginning at start of second week. Rituximab is also administered 3 times per week for 4 weeks using a fixed dose of 100 mg on Day 1 and a dose of 375 mg/m2 for all subsequent doses.~Drug Course 2: plerixafor (20 mg/m) same dose as course 1. Dosing 3 times/week for 4 weeks. Rituximab is also administered 3 times per week for 4 weeks using a dose of 375 mg/m2 for all doses.
Study NCT01881932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture using Seirin® needles
Description: Participants will receive acupuncture weekly until the end of chemotherapy.~Subjects will receive acupuncture at documented acupoints. To improve blinding effect, the acupuncturist will also tap 2 guiding tubes at 2 sham points , and immediately affix a pair of needles to the surface of the same points with adhesive tape, without needle insertion.
Study NCT01881932 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Acupuncture using Park Sham placebo acupuncture device
Description: Participants will receive sham acupuncture until the end of chemotherapy.~Acupuncturist will insert Park Sham Devices, non-penetrating sham acupuncture device consisting of a retractable needle and an adhesive tube into the sham points, and then immediately apply 2 pieces of adhesive tape next to the needles. In addition, she will tap a mock plastic needle guiding tube on the surface of each of the 8 true points in the arm and leg to produce some discernible sensation and then immediately apply a needle with a piece of adhesive tape to the dermal surface, without needle insertion.
Study NCT01929603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic sampling
Description: Blood sampling to measure olaparib, rifampicin and 4β-hydroxycholesterol